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Abstract
Background: Autoimmune pancreatocholangitis (AIPC) is an emerging, not completely characterized disease. Aim of this
study was the comprehensive evaluation of a series of AIPC patients, who were diagnosed and treated in a European
institution between January 2003 and July 2006.
Methodology/Principal Findings: Thirty-three patients with histologically confirmed AIPC were analyzed and compared to
20 patients with non-autoimmune chronic pancreatitis (CP) and 14 patients with primary sclerosing cholangitis (PSC).
Clinical features and conventional histopathology were taken into account. Immunohistochemistry and real-time
quantitative PCR were used for the characterization of the inflammatory infiltrate and the stromal reaction. AIPC was
localized in the pancreatic head in 94% of the patients. Intra- and/or extrapancreatic biliary tract involvement was present in
64% of the cases. The number of infiltrating T-lymphocytes, macrophages and total plasma cells was significantly higher in
AIPC than in CP (3-, 4- and 8-fold increase, respectively). The absolute number of IgG4-positive plasma cells was higher in
AIPC than in CP and PSC (7-fold and 35-fold increase, respectively), but significance was only reached in comparison with
PSC. CXCR5- and CXCL13-positive cells were almost exclusively detected in AIPC.
Conclusions/Significance: AIPC is mainly a disease of the pancreatic head with possible extension into the periphery of the
gland and/or into the biliary tract/gallbladder. The morphology of AIPC, as well as the immune- and stromal reaction is
characteristic and comparable between cases with and without biliary tract involvement. Immunological markers (IgG4,
CXCR5, CXCL13) can be of diagnostic relevance in specific settings.
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Introduction
Autoimmune pancreatitis (AIP) is a recently recognized
clinicopathological entity, which was first described by Sarles in
1961 as a ‘‘chronic inflammatory sclerosis of the pancreas’’ of
possible autoimmune pathogenesis associated with hypergamma-
globulinemia.[1] The disease has been gaining new attention for
the last two decades, and the term ‘‘autoimmune pancreatitis’’,
coined by Yoshida in 1995,[2] has only recently been widely
accepted in the scientific literature.[3] Due to the possible
involvement of the biliary tract, the term autoimmune pancrea-
tocholangitis (AIPC) has been introduced.[4,5] The main reasons
for the rising interest in investigating AIPC reside in its increasing
frequency, partly due to an increased awareness of the disease but
also due to a potentially increased incidence in the last 20–30
years,[6,7] its not yet clarified aetiology and pathogenesis and its
still undefined clinical spectrum. Unfortunately, international
consensus criteria for the diagnosis of AIPC are still missing.[8]
The coexistence of AIPC with other autoimmune-related diseases,
such as Sjo ¨gren’s syndrome, inflammatory bowel diseases (IBD)
and rheumathoid arthritis, the presence of immunologic abnor-
malities in subsets of patients (hypergammaglobulinemia, elevated
serum IgG4 levels, presence of autoantibodies), and the association
with a specific HLA-haplotype in the Japanese population,
represent the main pieces of evidence of an autoimmune
pathogenesis of the disease.[9,10] Such evidence has been further
supported by an animal model of an AIP-like form of chronic
pancreatitis in neonatally thymectomized mice immunized with
lactoferrin or carbonic anhydrase II.[11] Autoantibodies against
lactoferrin or carbonic anhydrase isozymes are present in
subgroups of AIPC patients [12,13] and elevated carbonic
anhydrase II autoantibodies are associated with increased serum
IgG4 levels.[14] The clinical and serological features of AIPC are
far from being uniform, so that a preoperative diagnosis is difficult
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surgery.[15] Elevated serum levels of IgG4 have been reported to
be of diagnostic value in some series,[16,17] whereas other groups
have shown that a mild (#2-fold) elevation of IgG4 levels can also
occur in other settings, such as non-autoimmune chronic
pancreatitis and pancreatic cancer.[18] The immunohistochemical
evaluation of IgG4-positive plasma cells in pancreatic tissues has
been proposed as an alternative marker of AIPC.[19] However,
the use of this parameter in biopsy material is impaired by the
patchy distribution of IgG4-positive cells in AIPC.[6]
This complex and controversial scenario renders the analysis of
large series of histologically confirmed AIPC necessary, in order to
accumulate further data that can improve and extend the present
knowledge about this challenging disease.
In this single institutional study, a collective of 33 patients with
histologically proven AIPC is presented and characterized from
the clinical and pathological point of view, with particular
attention to the biliary tract involvement and to the analysis of
the inflammatory response and the stromal reaction. The results
are compared with those obtained in two control groups,
consisting of histologically confirmed non-autoimmune chronic
pancreatitis and primary sclerosing cholangitis. In order to define
distinct and discriminative features of AIPC, the number and
distribution of B and T lymphocytes, macrophages and plasma
cells, including the subclass of IgG4-positive plasma cells, were
analyzed. Moreover, the expression of CXCL13 (BCA-1, B-cell
attracting chemokine 1) and CXCR5 (BLR1, Burkitt lymphoma
receptor-1) was examined, aiming at identifying further AIPC-
specific tissue markers possibly related to the autoimmune
pathogenesis of this disorder. CXCL13 and CXCR5 are in fact
involved in normal lymphocyte trafficking and homing in
secondary lymphoid organs and are highly expressed in various
autoimmune diseases characterized by the occurrence of ectopic
lymphoid follicles [20–23], which are also a prominent feature of
AIPC. The peculiar morphological aspect of the AIPC-associated
fibrosis, also termed ‘‘inflammatory storiform fibrosis’’ [24] due to
the presence of inflammatory cells and plump myofibroblasts
within irregular whorls of collagen bundles, prompted the further
characterization of the stroma composition, in an attempt to
provide an insight into the molecular basis of different patterns of
pancreatic fibrosis.
Materials and Methods
Patients and tissue collection
Thirty-one cases of AIPC were diagnosed among 320 patients
with histologically proven chronic pancreatitis operated on
between January 2003 and July 2006 at the Department of
Surgery of the University of Heidelberg, thus representing 9.7 % of
all CP-patients, who received surgical therapy at this institution.
Twenty-four AIPC patients (73%) underwent surgical exploration/
resection under the suspicion of a malignant pancreatic tumour.
Two of them (patients 31 and 33, see Table 1) showed involvement
of the extrahepatic biliary tree with morphological similarities to
autoimmune pancreatitis and were therefore included in this series.
AIPC-patients 2–9, 11–14,16–17, 25,30 and 32 had been included
in a previously published series focused on clinical aspects of the
disease.[15] The group of AIPC patients was compared to a cohort
of 20 patients (16 males, 4 females) affected by non-autoimmune
CP (30% with confirmed chronic alcohol abuse) as well as to a
group of 14 patients (10 males, 4 females) affected by PSC. Of the
14 PSC patients, 11 (78%) were subjected to liver transplantation
due to end-stage disease. Two patients with mostly peripheral
disease were treated either by duodenum-preserving pancreatic
head resection (DPPHR) with cholecystectomy or by cholecystec-
tomy alone. Eleven PSC patients (78%) were affected by ulcerative
colitis and 1 patient (7%) by Crohn’s disease. Formalin-fixed
paraffin embedded tissue samples were available from all patients.
Snap-frozen tissues preserved at 280uC for RNA extraction were
available from 7 AIPC cases (pancreas), 5 non-autoimmune CP
cases (pancreas) and 5 PSC cases (liver).
The study was approved by the ethics committee of the
University of Heidelberg, Germany, thus written informed consent
was obtained from all patients.
Clinical features and follow-up
Clinical and follow-up information was obtained from the clinical
records and in some cases by direct contact with the patient.
Together with the demographic characteristics, the following
features were recorded: history of CP in the family, personal history
of alcohol abuse, gallstones, autoimmune-related diseases (in
particular Sjo ¨gren Syndrome, ulcerative colitis, Crohn’s disease),
main symptoms, and preoperative laboratory values. Data about
serum immunoglobulin levels were available in 9 patients. In the
follow-up analysis, the development of known AIP-related diseases
(for example, sialadenitis, inflammatory bowel disease, tubulone-
phritis, retroperitoneal fibrosis) was also taken into account.
Histology, immunohistochemistry and morphometry
Routine histological examination of formalin-fixed, paraffin-
embedded tissue sections stained with hematoxylin and eosin
(H&E) obtained from pancreatic specimens was performed by two
experienced pathologists (IE and FB) with special training in
pancreatic pathology. The diagnosis and grading of severity and
activity of AIP were assessed according to previously described
criteria.[24] All the non-autoimmune CP specimens were scored
according to a previously reported system.[25] All PSC specimens
were retrieved from the archives of the Institute of Pathology of the
University of Heidelberg and comprehensively reviewed for the
purposes of the present study.
Immunohistochemistry was performed according to the strep-
tavidin-biotin method using diaminobenzidine as a chromogen, as
previously described.[26] For the CXCL13, CXCR5 and a-SMA
staining, the Envision
TM Detection-System (DakoCytomation,
Hamburg, Germany) was used. All other reagents were from
KPL (Kirkegaard and Perry Laboratories, Gaithersburg, MD,
USA). The antibodies used in this study and the respective
protocols are shown in Table 2. Morphometric analysis of the
inflammatory infiltrate was performed by measuring the whole
tissue area of each section with the computer program Image-ProH
Plus version 5.1 (IPWIN32.exe-Software, Weiss Imaging and
Solutions, Bergkirchen/Gu ¨nding, Germany) and counting the
stained cells with the aid of an image analyser (Olympus Soft
Imaging Solutions, Mu ¨nster, Germany). The intensity of immu-
nostaining of the stromal reaction was semiquantitavely evaluated
(absent=0; mild=+; moderate=++; strong=+++).
Real-time quantitative PCR
All reagents for mRNA extraction and cDNA synthesis were
from Roche Applied Science (Mannheim, Germany). mRNA was
isolated with the MagNA Pure LC Instrument using the Isolation
Kit II. cDNA was synthetized using the First Strand cDNA-
Synthesis-Kit for RT-PCR (AMV). The LightCycler FastStart
DNA SYBR green kit was employed for the PCR analysis. The
number of specific transcripts was calculated for the standard
curve and normalized to two houskeeping genes CPB (Cyclophilin
B) und HPRT (Hypoxanthin Phosphoribosyltransferase). All
primers were from Search LC (Mannheim, Germany).
Autoimmune Pancreatitis
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Statistical analysis was performed with the software program
GraphPad Prism4 (GraphPad Software, San Diego, CA, USA).
Dataareexpressedasmean(6SEM),unlessotherwisespecified.The
Student’s t-test or the non-parametric Mann-Whitney U-test was
used for comparisons, where appropriate. Associations between
clinical and pathologic features were assessed by the Fisher’s exact
test or the x
2 test. Significance was defined as p#0.05.
Results
Clinical and morphological characterization
Clinical data and follow-up. Most AIPC-patients (84%)
were middle-aged men (44631 years old, median6IQR).
Obstructive jaundice and/or abdominal/back pain were the
most common pre-operative symptoms and elevated values of
pancreatic enzymes and cholestasis parameters were the most
Table 1. Clinicopathological characteristics of AIPC patients.
Patient Sex Age
Clinical
presentation
Preoperative
diagnosis Surgical treatment Site of disease
Serum
IgG4 (g/l)
Follow-up/
associated
diseases Grading Activity
1 M 48 jaundice tumour PD Intrapancreatic - ok 2 low
2 M 44 pain tumour ppPD Intrapancreatic - ok 4 low
3 M 33 pain pancreatitis DPPHR Intrapancreatic - ok 3 high
4 M 34 pain tumour PD Intrapancreatic 0.39 - 2 low
5 F 50 pain tumour ppPD Intrapancreatic - ok 3 high
6 M 23 pain unclear Segmental resection Intrapancreatic - ok 3 low
7 M 33 pain unclear DPPHR Intrapancreatic 0.4 ok 3 low
8 M 37 jaundice tumour ppPD Intrapancreatic 0.2 ok 4 low
9 M 64 pain, jaundice unclear PD Intrapancreatic - AIP rec. 3 low
10 F 40 pain tumour ppPD Intrapancreatic - SLE 2 high
11 M 32 pain tumour ppPD Intrapancreatic - - 3 high
12 M 16 pain/jaundice tumour ppPD Intrapancreatic - cholangitis 3 low
13 M 33 pain/jaundice tumour ppPD intrapancreatic 10.91 - 4 low
14 M 22 pain/jaundice tumour ppPD intrapancreatic 0.31 IBD (UC) 3 high
15 M 70 pain/jaundice tumour ppPD intrapancreatic 1.7 ok 4 low
16 M 66 pain tumour ppPD intrapancreatic - ok 3 low
17 M 58 pain/jaundice tumour ppPD intrapancreatic - ok 4 low
18 M 70 jaundice tumour ppPD intrapancreatic - ok 4 high
19 M 40 pain pancreatitis ppPD intrapancreatic - ok 3 low
20 F 26 pain tumour ppPD intrapancreatic 0.4 ok 2 low
21 M 53 jaundice tumour DPPHR intrapancreatic - - 3 low
22 M 78 jaundice cystic tumour ppPD intrapancreatic - - 3 low
23 M 21 jaundice pancreatitis ppPD intrapancreatic - - 3 low
24 M 48 jaundice pancreatitis PD intrapancreatic 1.9 - 4 low
25 F 39 pain unclear ppPD intrapancreatic - ok 2 high
26 M 42 pain tumour ppPD intrapancreatic - IBD (UC)
# 3l o w
27 M 65 pain, jaundice tumour ppPD intra/extrapancreatic
(cystic duct)
- ok 4 low
28 M 64 pain cystic tumour ppPD intrapancreatic - ok 2 high
29 F 49 pain tumour Left subtotal
pancreatectomy
intrapancreatic 0.51 ok 4 low
30 M 77 jaundice tumour ppPD intra/extrapancreatic (GB) - ok 2 high
31 M 64 jaundice tumour Left hemihepatectomy extrapancreatic (liver, EBD) - dead * *
32 M 54 pain pancreatitis ppPD intra/extrapancreatic (GB) - ok 4 low
33 M 36 pain tumour EBD resection, bilio-
digestive anastomosis
extrapancreatic (EBD, IBD) - cholangitis * *
PD: pancreaticoduodenectomy; ppPD: pylorus-preserving pancreaticoduodenectomy; DPPHR: duodenum-preserving pancreatic head resection; GB: gallbladder;
EBD: extrahepatic bile duct; IBD: intrahepatic bile duct.
ok: no evidence of recurrent disease/associated disease; no disease/operation-associated symptoms.
-: not available; n: normal; SLE: systemic lupus erythematosus; IBD: inflammatory bowel disease; UC: ulcerative colitis.
#UC known pre-operatively.
*grading and activity not determined since no pancreatic tissue available.
1normal range: 0.052–1.25 g/l.
doi:10.1371/journal.pone.0002539.t001
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measured in 9 patients and a 4.4-fold increase was found in 1 of
them (12%). Three patients (9%) had an extrapancreatobiliary
autoimmune-related disease (2 cases with ulcerative colitis, 1 case
with systemic lupus erythematosus). The detailed demographic
and clinical characteristics of AIPC-patients are shown in Table 1.
Table 3 shows a comparison of the main clinical and laboratory
findings in the different disease groups. When the AIPC-cases with
and without extrapancreatic biliary tract involvement (AIPC
extrapancreatic and AIPC intrapancreatic, respectively) were
considered separately, the results of the comparison of the entire
AIPC group with CP and PSC were confirmed (Table 3). No
significant differences in the comparison between AIPC intra- and
extrapancreatic were found (not shown).
Morphology
Pancreas
Typical features of AIP were present in all cases in which
pancreatic tissue was available for the macroscopical and histological
analysis (n=31) (Figure 1, A–F). No patient had calculi or
calcifications of the pancreatic parenchyma, irregular duct dilatation
or anatomical anomalies (e.g. pancreas divisum), which are typically
associated with chronic pancreatitis. They rather showed a diffuse
enlargement of the pancreas, mostly (n=29, 94%) localized in the
pancreatic head. Patient 28 had in addition an inflammatory
pseudocyst of the pancreatic head, a rare finding in AIP. This case
has been published previously.[27] Regarding the histological grade
ofseverityofthedisease, seven patients (23%) had a score 2,fourteen
patients (45%) a score 3, and ten patients (32%) a score 4. The
activity of the inflammatory process was scored as ‘‘low’’ (=absence
of/focal granulocytic epithelial lesions, GEL; no significant granu-
locytic infiltrate in the acinar parenchyma) in 22 patients (71%) and
as ‘‘high’’ (=multifocal GEL with intraductal abscess formation;
granulocytic infiltrate in the acinar parenchyma) in 9 patients (29%)
(Table 1). Grade and activity did not correlate. Cases with high
activity had more frequently elevated serum levels of pancreatic
enzymes(amylaseand/orlipase)thancaseswithlowactivity,butthe
difference was not statistically significant.
All 20 CP patients revealed the typical features of non-
autoimmune CP, with mainly interlobular or diffuse fibrosis,
atrophy of the acinar parenchyma, dilatation of the pancreatic
ducts (18 cases, 90%), calcifications (9 cases, 45%), necroses (12
cases, 60%), and pseudocysts (5 patients, 25%). According to a
previously established scoring system, the severity of the
inflammatory process was mild (score 1) in 6 patients (30%),
moderate (score 2) in 10 patients (50%), and severe (score 3) in 4
cases (20%). Morphological features of AIP, such as periductal
inflammation, GEL, venulitis, and/or arteriitis were absent in all
cases. Scattered lymph follicles within and around the pancreatic
parenchyma were observed in 13 cases (65%).
Biliary tree
A typical morphological finding in AIPC was the involvement of
the intrapancreatic bile duct, which was severely affected by the
inflammatory process with stenosis of the lumen in 16 cases (48%).
In addition, three patients (patients 27, 30 and 32) showed an
extension of the disease into the extrapancreatic biliary tree, with
involvement of the common bile duct/cystic duct/gallbladder.
Furthermore, in patients 31 and 33 the histological analysis of the
extra- and/or intrahepatic bile duct showed typical AIPC-like
changes, so that a total of 5 patients (15%) showed extrapancreatic
Table 2. Antibodies and protocols for immunohistochemistry.
Antigen/Clone Cell type/Site of expression{ Company Dilution Antigen retrieval Detection system
IgG4/HP 6025 Plasma cells Zymed Laboratories Inc, San
Francisco/USA
1:1000 1 mM EDTA (pH=8.0) Streptavidin-Peroxidase
Syndecan/MI15 Plasma cells Dako-Cytomation 1:25 Citrate buffer (pH=6.0) Streptavidin-Peroxidase
CD5/54/F6 T lymphocytes Dako-Cytomation 1:25 Tris-EDTA-Buffer (pH=9.0) Streptavidin-Peroxidase
CD20/L26 B lymphocytes Dako-Cytomation 1:100 Dako Target Retrieval
Solution (pH=6.1)
Streptavidin-Peroxidase
CD68/KP1 Macrophages Dako-Cytomation 1:1000 Citrate Buffer (pH=6.0) Streptavidin-Peroxidase
CXCL13/53610 Follicular dendritic cells R&D Systems, Minneapolis/USA 1:20 Dako Target Retrieval
(pH=9.0) solution
Envision
B lymphocytes
Macrophages
CXCR5 B lymphocytes Abcam, Cambridge/UK 1:100 Citrate buffer (pH=6.0) Envision
Subsets of T lymphocytes
SMA/1A4 Activated stellate cells Dako-Cytomation 1:150 None Envision
Smooth muscle cells
TenascinC/BC-24 Activated stellate cells Abcam, Cambridge/UK 1:4000 Pronase 1:10 Streptavidin-Peroxidase
Extracellular matrix
Collagen I/COL1 Extracellular matrix Abcam, Cambridge/UK 1:50 None Streptavidin-Peroxidase
Collagen III Extracellular matrix SantaCruz Biotechnology Inc., USA 1:500 None Streptavidin-Peroxidase
Collagen V Activated stellate cells SantaCruz Biotechnology Inc., USA 1:200 None Streptavidin-Peroxidase
Extracellular matrix
Collagen VI Extracellular matrix SantaCruz Biotechnology Inc., USA 1:200 None Streptavidin-Peroxidase
{only the expression sites relevant to the present study are indicated.
doi:10.1371/journal.pone.0002539.t002
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features of the biliary tract involvement were comparable to the
typical intrapancreatic findings, i.e. a periductal, mostly mononu-
clear cell infiltrate rich in plasma cells with only focal detachment of
the overlying epithelium and a ‘‘storiform’’ fibrosis of all layers of the
wall with stenosis of the lumen (Figure 1G). In case 31, a left
hemihepatectomy was performed under the suspicion of liver
metastases. The histopathological examination of the liver revealed
parenchymal atrophy with enlarged portal tracts showing periductal
chronic inflammation and obliteration of the bile ducts. No
laboratory or conventional histologic parameter was predictive of
the extrapancreatic bile duct involvement in the cases with
pancreatic disease.
PSC patients that underwent liver transplantation displayed by
histological analysis the typical features of biliary cirrhosis. In two
patients with peripheral disease, the gallbladder showed peri-
glandular dense lymphoplasmocytic infiltration with focal epithe-
lial detachment and periductal fibrosis, which however did not
have the dense and storiform pattern observed in AIPC cases with
biliary tract involvement and which was limited to the upper third
of the organ’s wall (Figure 1H).
Comparative analysis of the inflammatory and stromal
reaction
Inflammatory infiltrate. The morphological characteriza-
tion of the inflammatory infiltrate showed a clear-cut predominance
of mononuclear cells. However, the number and distribution of the
different cell types, as shown by the immunohistochemical analyses,
were quite different. In detail, the number of B- and T-lymphocytes,
macrophages and in particular of plasma cells was higher in AIPC
with and without biliary tractinvolvement than inCPand PSC.The
absolute number of IgG4-positive plasma cells was higher in AIPC
(both groups) compared to CP and PSC. The group with the highest
number of IgG4-positive plasma cells was that of AIPC with
involvement of the extrapancreatic biliary tract. However, when the
number of IgG4-positive plasma cells was normalized to the total
number of plasma cells, as determined by CD138 staining, no
significant differences between the different groups were found
(Figure 2), indicating that there was no selective increase of IgG4-
positive plasma cells compared to the other subclasses. Only in the
group of AIPC with intrapancreatic involvement there was a slightly
significant increase in the IgG4-CD138 ratio in comparison with
non-autoimmune CP (p=0.04). Regarding the localization, the
inflammatory cells were present both within and outside the
pancreas (in the peripancreatic adipose tissue) in AIPC, whereas
they were mostly intrapancreatic in CP. In AIPC, B- and T-
lymphocytes and plasma cells often displayed a periductal
localization, which was not observed in CP. In PSC, the
inflammatory cells were distributed in a diffuse fashion or in small
clusters in the cirrhotic septa or in the mucosal layer of the
gallbladder.
The number of CXCR5-positive cells was significantly higher in
AIPC (both subgroups) than in the other disease groups, with a
mostly periductal and diffuse parenchymal localization. CXCL13-
positive cells were only found in the AIPC groups in a periductal
and diffuse parenchymal localization. To confirm the overexpres-
sion of CXCR5 and CXCL13 in AIPC, real-time quantitative
PCR was additionally performed. Median CXCR5-mRNA levels
in AIPC showed a 4.1-fold increase in comparison with CP
(p=0.02) and a 32-fold increase in comparison with PSC
(p=0.005). Median CXCL13-mRNA levels in AIPC were also
significantly higher than in the other groups, with a 21-fold
increase compared to CP (p=0.01) and a 22-fold increase
compared to PSC (p=0.002) (Figure 3).
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PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2539No significant differences in cell count and distribution were
observed when AIPC with and without extrapancreatic extension
were compared to each other (not shown). The immunohisto-
chemical characterization of the inflammatory infiltrate is shown
in Table 4 and exemplarily illustrated in Figure 4 (panels A–L).
Stromal reaction. The morphological analysis of the stromal
reaction revealed increased extracellular matrix deposition in all
different disease groups. Collagen I, III, V and VI were all expressed
in the AIPC and CP group, although with different patterns and
intensities. Collagen I staining was mostly weak in the AIPC group,
where it showed a preferentially interlobular localization. In CP,
collagen I staining was generally more intense, in particular in score
3 cases. Collagen III staining was moderate to intense in the AIPC
groupanditshowedamostlyperiductallocalization.InCP,intensity
and pattern of expression of collagen III were overlapping with those
of collagen I. Collagen V immunostaining revealed a moderate
Figure 1. Histopathological features of AIPC. (A) Overview of pancreatic parenchyma with typical AIPC changes. In the center, a duct (*) with
periductal mononuclear infiltration and fibrosis. Interlobular fibrosis is shown (arrows). (B) Interlobular duct with moderate periductal mononuclear
infiltration, fibrosis and beginning stenosis of the lumen. (C) Higher magnification of an interlobular duct with early granulocytic epithelial lesion
(GEL). Note the few neutrophils that infiltrate through the basal membrane into the epithelium (arrows). (D) Advanced GEL with abscess formation (*)
in the lumen of an interlobular duct. (E) Lymphoplasmocytic inflammation of the wall of a small peripancreatic vein (*). Note the extension of the
inflammatory infiltrate into the peripancreatic fat (arrows). (F) Lymphoplasmocytic inflammation of the wall of a small-sized intrapancreatic artery (*).
(G) Involvement of the gallbladder in a case of AIPC. In the mucosa, a dense lymphoplasmacytic infiltrate below an almost intact epithelium. Note the
thickening of the wall, due to the fibrosis and the extension of the inflammation into the deeper layers (arrows, inset). (H) Involvement of the
gallbladder in a case of primary sclerosing cholangitis. Here, also a predominant lymphoplasmacytic inflammation with focal erosions of the
epithelium and only superficial fibrosis. The deeper portions of the gallbladder wall are intact (inset).
doi:10.1371/journal.pone.0002539.g001
Autoimmune Pancreatitis
PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2539extracellular expression as well as a moderate to strong expression in
stromal fibroblasts in the AIPC group, with a preferential
interlobular and periductal localization. In the CP group, a
moderate, mostly extracellular interlobular collagen V staining was
found. Collagen VI was also strongly expressed in the AIPC group
(interlobular and periductal), whereas it was relatively weak in CP
tissues. PSC tissues displayed a diffuse, weak to moderate positivity
forcollagenI andVI inthe cirrhoticsepta. Nosignificantstaining for
collagen III or V was found in PSC.
Cytoplasmic a-SMA expression in stromal fibroblasts and
extracellular tenascin C expression displayed overlapping localiza-
tions. In all three groups, the intensity of the staining was moderate
to intense. In AIPC, the staining was mostly periductal and inter-/
intralobular, consisting of broad stained areas of connective tissues
Figure 2. Quantitative evaluation of the IgG4-positive cells and of the IgG4/plasma cell ratio. (A) Total number of IgG4-positive cells and
(C) IgG4/CD138 ratio in the disease groups of AIPC total, CP and PSC. (B) Total number of IgG4-positive cells and (D) IgG4/CD138 ratio when the AIPC
cases are subclassified in those with and without extrapancreatic biliary tract involvement (AIPC extrapancreatic and AIPC intrapancreatic,
respectively). Y-axis indicates the number of positive cells/mm
2 in a logarithmic scale for better representation. Horizontal bars represent mean. *
indicates statistical significance (p#0.05).
doi:10.1371/journal.pone.0002539.g002
Figure 3. Real-time quantitative PCR analysis of CXCR5 and CXCL13. Real-time quantitative RT-PCR analysis of pancreatic tissues showing
significantly higher levels of CXCL13 (A) and CXCR5 (B) mRNA in AIPC than in CP and PSC. RNA input was normalized to the average expression of the
two housekeeping genes HPRT and cyclophilin B as described in Methods. Y-axis indicates the relative amount of mRNA in a logarithmic scale for
better representation. Box and whiskers blot with 10–90 percentile are shown. * indicates statistical significance (p#0.05).
doi:10.1371/journal.pone.0002539.g003
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PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2539betweentheacinarlobuli.InCP,thestainingwasalsoperiductaland
interlobular, but less extensive and often localized to a thin band of
connective tissue just around the acinar lobuli. Finally, in PSC, the
staining was diffuse in the cirrhotic septa, often with a strongly
positive band just around the cirrhotic nodules. The immunohisto-
chemical characterization of the stromal reaction is exemplarily
showninFigure4(panelsM–T).QuantitativePCRanalysisrevealed
higher Tenascin C and a-SMA mRNA levels in AIPC compared to
Figure 4. Immunohistochemical characterization of AIPC, CP and PSC. (A–H) Immunohistochemical characterization of the inflammatory
infiltrate of AIPC. (A) CD20-positivity of B-lymphocytes in periductal localization and with tendency to form lymph follicles (arrow). (B) CD5-positive T-
lymphocytes with diffuse arrangement around an interlobular duct. (C) Scattered CXCR5-positive cells (arrowheads) around the main pancreatic duct.
(D) CXCL13-positive cells arranged in small clusters in the pancreatic tissue. (E) Numerous CD138-positive plasma cells in a diffuse arrangement in the
pancreatic parenchyma. (F–G) IgG4-positive cells diffusely distributed in the peripancreatic adipose tissue (F) and in a periductal localization (G). (H)
Isolated IgG4-positive cells (arrow) below the epithelium of the gallbladder in a case of AIPC with extrapancreatic biliary involvement. (I–K)
Immunohistochemical characterization of the inflammatory infiltrate in CP. (I) A few CD138-positive plasma cells in a diffuse arrangement in
pancreatic scar tissue. (J–K) IgG4-positive cells in large (J) and small (K) clusters in the pancreatic parenchyma. (L) Isolated IgG4-positive cells (arrow) in
the gallbladder of a patient affected by PSC. (M–P) Immunohistochemical characterization of the stromal reaction in AIPC. (M) Low-power view of
pancreatic tissue shows a weak (+) to moderate (++) interstitial staining for collagen I. (N) Moderate (++) to strong (+++) interlobular and periductal
(inset) collagen V staining. (O) Strong (+++) diffuse and periductal (inset) a-smooth muscle actin (a-SMA) staining. (P) Diffuse interlobular and strong
(+++) periductal (inset) positivity for Tenascin C. (Q–T) Immunohistochemical characterization of the stromal reaction in CP. (Q) Moderate (++)
interlobular collagen I staining. (R) Very weak (2/+) interlobular collagen V staining. (S) Moderate (++) positivity for a-SMA in the interlobular
connective tissue, without periductal arrangement (inset, here notice the extensive squamous cell metaplasia of the duct epithelium). (T) Moderate
(++) staining for Tenascin C at the interface between the pancreatic lobules and the interlobular connective tissue.
doi:10.1371/journal.pone.0002539.g004
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PLoS ONE | www.plosone.org 8 July 2008 | Volume 3 | Issue 7 | e2539the other diseases. In detail, Tenascin C m-RNA levels displayed a
5.5-fold increase in AIPC compared to CP (p=0.005) and a 3.7-fold
increase compared to PSC (p=0.07). a-SMA mRNA levels in AIPC
were 10.4-fold higher than in CP (p=0.03) and 11.4-fold higher
than in PSC (p=0.04).
Discussion
Despite progress in its clinical, radiological and morphological
characterization in recent years, AIPC still remains an elusive
disease. Its aetiology is unknown, its pathogenesis is only partly
understood, and international consensus criteria for its diagnosis
are still missing.[8] The fact that four different working groups
have proposed their own diagnostic criteria [28–31]–although it
may in part reflect heterogeneity of the disease in different parts of
the world–clearly highlights the level of uncertainty in the
approach to AIPC. Some recently published AIPC collectives
[6,24,28,32,33] as well as numerous case reports have further
improved the understanding of some aspects of the disease. Our
patients’ cohort represents one of the largest European single-
centre series and in its clinical characteristics correlates well to the
previously reported collection of cases.
Extra- and/or intrahepatic bile duct lesions histologically
characterized by a dense infiltrate of IgG4-positive plasma cells
have been reported in up to 74% of AIP-patients, [34] leading to the
proposal of an entity called autoimmune IgG4-associated cholangitis
[35] and questioning the existence of a previously reported
association between AIP and primary sclerosing cholangitis.
According to our data, AIP-associated biliary tract involvement,
which was histologically proven in 64% of our cases (15%
extrapancreatic), should not be regarded as a mere extrapancreatic
manifestation of AIP, but rather as a subtype/sublocalization of a
disease, which affects the pancreatic duct–usually in the pancreatic
head–and may extend to the biliary system. More appropriately, this
entity has been recently defined as autoimmune pancreatocholangi-
tis (AIPC). [5] The AIPC-concept, which has been first suggested by
Zen et al.,[36] relies on the embryological and morphological
similarities between the ductal system of the pancreas and the biliary
tract, and is also supported by the results of the present study, which
demonstrate that the biliary tract involvement shares morphological
and immunological characteristics with the pancreatic involvement
itself and differs clearly from other biliary tract diseases, such as
PSC.[37] Clinical aspects, such as patients’ age (significantly higher
in AIPC patients with extrapancreatic biliary involvement) and the
consistent association of PSC with ulcerativecolitis appeared to be of
further help in distinguishing extrapancreatic AIPC from PSC.
Histopathology was the entry criterion used for the inclusion of
AIPC cases in this study, according to previously described
parameters,[24] whose validity could be confirmed also regarding
the biliary tract manifestations of the disease. The similarity
between the two subgroups of AIPC was further confirmed when
the inflammatory infiltrate was examined in the different settings.
In particular, the number of infiltrating B- and T-cells,
macrophages and plasma cells was significantly higher compared
to CP and, in the case of plasma cells, also compared to PSC.
Another useful differential parameter was the number of CXCR5
and CXCL13-positive cells, which were found, although in small
numbers, only in AIPC subgroups. CXCL13 and its receptor
CXCR5 are involved in the organization and compartmentaliza-
tion of lymph follicles and are overexpressed in various
autoimmune diseases, like rheumatoid arthritis, Sjo ¨gren’s syn-
drome, Hashimoto’s thyreoiditis and Graves’ disease, and in gut
associated lymphoid tissue (GALT) of patients affected by
ulcerative colitis.[20–23] This novel finding provides a further
functional link between AIPC and some of the most frequently
reported AIPC-associated conditions, such as Sjo ¨gren’s syndrome
and ulcerative colitis and gives further support to the still debated
hypothesis of an autoimmune pathogenesis of AIPC. In analogy to
mechanisms postulated in other autoimmune disorders [23], the
formation of ectopic lymph follicles with germinal centers where B
cells undergo maturation and activation, driven by the CXCL13-
CXCR5 interaction, would therefore be essential for the
pathogenesis of AIPC. Mature plasma cells would then synthesize
large amount of immunoglobulins, which participate in tissue
damage for instance by forming immune complexes.[33] The
number of IgG4-positive plasma cells has been frequently reported
as a useful tissue marker for the differential diagnosis between
AIPC and other pancreatic/biliary diseases [6,36,38,39] and for
the differentiation of postulated morphological subtypes of
AIP.[33] In the present study, the absolute number of IgG4-
positive cells was higher in the AIPC group compared to both CP
and PSC, although statistical significance was reached only in
comparison with the PSC group. However, since the IgG4/plasma
cell ratio was not different between groups, the observed increase
of IgG4-positive cells in AIPC appears to be simply due to an
increase in the total number of infiltrating plasma cells.
Table 4. Overview and comparison of the immunohistochemical analysis of the inflammatory infiltrate in AIPC, CP and PSC.
AIPC total
AIPC intra-
pancreatic
AIPC extra-
pancreatic CP PSC
AIPC total
vs CP
AIPC total
vs PSC
AIPC intra-
pancreatic
vs CP
AIPC extra-
pancreatic
vs CP
AIPC extra-
pancreatic
vs PSC
CD20 13.463.4 13.664 12.262 6.161.4 6.961.4 ns ns ns ns ns
CD5 11.362.7 12.463.2 6.563 3.461.04 4.161.3 0.01 ns 0.01 ns ns
CD68 9.261.7 961.7 10.465.6 2.360.5 6.462.1 0.002 ns 0.002 0.008 ns
CD138 18.964.05 16.864.4 26.869.6 2.460.9 6.762.6 0.01 0.04 0.02 0.003 0.01
IgG4 2.861.3 2.461.6 4.361.4 0.460.1 0.0860.04 ns 0.0009 ns 0.004 0.001
IgG4/CD138 0.3260.2 0.3460.2 0.2660.1 0.2360.1 0.3360.2 ns ns 0.04 ns ns
CXCR5 0.460.09 0.460.1 0.1660.05 0.0260.01 0.0160.005 ,0.0001 ,0.0001 0.0001 0.005 0.003
CXCL13 0.2460.07 0.2660.07 0.160.05 0 0 -----
AIPC total: all AIPC cases are included; AIPC intrapancreatic: cases with no extension into the extrapancreatic biliary tract; AIPC extrapancreatic: cases with
extension into the extrapancreatic biliary tree.
Data are expressed as mean number of positive cells/mm
26SEM.
doi:10.1371/journal.pone.0002539.t004
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PLoS ONE | www.plosone.org 9 July 2008 | Volume 3 | Issue 7 | e2539The analysis of the stromal reaction indicated substantial
qualitative and quantitative differences in the composition and
distribution of the fibrosis. The stromal reaction was mainly
interlobular and periductal in AIPC and predominantly interlobular
in CP. Moreover, the increased expression of collagen V–a collagen
type that has been shown to accumulate in malignant disease [40]–
and the more diffuse distribution of Tenascin C–an ECM protein
that is overexpressed in pancreatic cancer [41]–and of aSMA in
AIPC compared to CP may account for the radiological and
macroscopic tumor-like appearance of AIPC. In addition, the
stroma composition could reflect distinct underlying mechanisms for
the development of fibrosis in CP and AIPC with a preferential
activation of pancreatic stellate cells, which express aSMA,Tenascin
C [41,42] and collagen V (unpublished observation), in AIPC.
In conclusion, our clinical, morphological and immunological
data support the existence of a possibly autoimmune-mediated
inflammatory disease of the pancreato-biliary system of unknown
cause, so-called autoimmune pancreatocholangitis (AIPC). AIPC
usually affects the pancreatic head and may extend to other parts
of the pancreas, as well as to the biliary tract. Morphological
parameters are the only reliable criteria for the diagnosis, whereas
the role of serum and/or tissue IgG4 and of CXCR5/CXCL13 as
possible disease markers warrants further investigation.
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